Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Niemann-Pick disease type C is a rare, autosomal recessive neurovisceral lipid storage disorder caused predominantly by biallelic variants in the NPC1 gene (HGNC:7897). Affected individuals present with visceral signs—prolonged neonatal jaundice, hepatosplenomegaly—followed by progressive neurological features including vertical supranuclear gaze palsy and cerebellar ataxia. The worldwide prevalence is estimated at 1:120 000–150 000 births, although founder effects have been described in specific populations. Early diagnosis is critical as substrate reduction therapy (miglustat) and supportive seizure management can stabilize neurologic decline.
The gene–disease relationship is classified as Definitive. Over 200 independent patients with confirmed biallelic NPC1 variants have been reported across multiple cohorts (>200 probands) (PMID:10480349; PMID:12408188; PMID:12955717). Segregation analyses in at least 20 families demonstrate autosomal recessive inheritance of pathogenic variants with complete cosegregation (PMID:10480349). Concordant functional data from cell, zebrafish, and mouse models underpin the clinical observations.
NPC1-related NPC is inherited in an autosomal recessive manner. Segregation studies in 20 affected relatives across unrelated families confirm biallelic transmission, with compound heterozygotes and homozygotes observed (PMID:12408188). More than 250 unique NPC1 variants have been described, including missense, nonsense, frameshift, splice-site, and deep-intronic changes. Variant spectrum comprises >140 missense substitutions and >60 loss-of-function alleles; some recurrent/founder mutations include c.2974G>T (p.Gly992Trp) in Nova Scotian Acadians and NM_000271.5:c.3182T>C (p.Ile1061Thr) in European populations (PMID:16778374; PMID:18216017). Example pathogenic variant: c.3182T>C (p.Ile1061Thr).
Loss-of-function is the predominant pathogenic mechanism, with mutant NPC1 proteins showing misfolding, ER-associated degradation, and impaired cholesterol export from lysosomes. Chemical chaperones rescue NPC1(I1061T) stability and restore cholesterol trafficking in patient fibroblasts (PMID:18216017). Zebrafish npc1 morphants exhibit defective early embryonic cell movements reversible by sterol supplementation (PMID:21576600). Mouse knock-in of an NPC1 N-terminal domain cholesterol-binding mutant reproduces full NPC phenotype, establishing the critical role of cholesterol binding (PMID:21896731). Autophagy is upregulated via Beclin-1 in NPC1 deficiency, linking lipid trafficking defects to neurodegeneration (PMID:17611388; PMID:17468177).
No robust evidence disputes the NPC1–NPC association. A small subset of “NPC variants” with near-normal filipin staining underscores the need for comprehensive genetic and biochemical testing to avoid false negatives (PMID:11349231).
Collectively, the abundant genetic and experimental data establish NPC1 as essential for endolysosomal cholesterol egress; pathogenic variants cause Niemann-Pick disease type C through loss-of-function. Genetic testing panels should include deep intronic regions and copy-number assays to capture rare pseudoexon and large deletion events. Early molecular diagnosis enables timely initiation of miglustat therapy and seizure control, improving neurological outcomes.
Key Take-home: NPC1 variant analysis is critical to confirm Niemann-Pick disease type C and guide early treatment decisions.
Gene–Disease AssociationDefinitive
Genetic EvidenceStrong
Functional EvidenceStrongCellular, zebrafish, and murine models demonstrate concordant loss-of-function and rescue |